Content about Estrogens

February 26, 2013

The Food and Drug Administration has approved a drug for postmenopausal women who experience pain during sex.

SILVER SPRING, Md. — The Food and Drug Administration has approved a drug for postmenopausal women who experience pain during sex.

The agency announced the approval of Shionogi's Osphena (ospemifene) for women with moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy due to menopause associated with declining levels of estrogen hormones.

January 30, 2013

A patch for treating menopause that the manufacturer calls the smallest is now available.

NEW YORK — A patch for treating menopause that the manufacturer calls the smallest is now available.

Noven Pharmaceuticals announced the availability of Minivelle (estradiol) transdermal system in pharmacies. The patch, which the Food and Drug Administration approved in October 2012, is designed for treating hot flashes and night sweats in women with menopause.

The patch has a surface area nearly the same as a dime at its lowest strength of 0.0375 mg-per-day and is 34% smaller than Noven's Vivelle-Dot patch, the company said.

June 29, 2012

The Food and Drug Administration has accepted a regulatory approval application for a drug made by Shionogi for treating vulvar and vaginal atrophy due to menopause.

FLORHAM PARK, N.J. — The Food and Drug Administration has accepted a regulatory approval application for a drug made by Shionogi for treating vulvar and vaginal atrophy due to menopause.

Shionogi, the U.S. division of Japanese drug maker Shionogi & Co., said Wednesday that the FDA had accepted for review its application for ospemifene, which the company touts as potentially the first oral alternative to vaginal estrogen treatments.

March 2, 2012

Watson has launched an authorized generic drug for treating postmenopausal women, the company said Friday.

PARSIPPANY, N.J. — Watson has launched an authorized generic drug for treating postmenopausal women, the company said Friday.

Watson announced the launch of progesterone capsules in the 100-mg and 200-mg strengths, an authorized generic version of Abbott Labs' Prometrium, under an agreement with Abbott. Abbott will manufacture the drug and supply it to Watson, which will market and distribute it and share profits. Other terms were not disclosed, the companies said.

November 21, 2011

Mylan will begin selling a generic drug for treating symptoms of menopause in two years, the company said Monday.

PITTSBURGH — Mylan will begin selling a generic drug for treating symptoms of menopause in two years, the company said Monday.

Following the settlement of a patent-litigation suit with Swiss drug maker Novartis over the patch Vivelle-Dot (estradiol transdermal system), Mylan said it had received a patent license to begin selling its version of the drug in December 2013.

March 2, 2011

A group of drug makers have sued Mylan over its attempt to gain Food and Drug Administration approval for a generic menopause drug, Mylan said Tuesday.

PITTSBURGH — A group of drug makers have sued Mylan over its attempt to gain Food and Drug Administration approval for a generic menopause drug, Mylan said Tuesday.

January 26, 2011

Smoking before menopause, especially prior to giving birth, may be associated with a modest increase in the risk of developing breast cancer, according to a report in the Jan. 24 issue of Archives of Internal Medicine.

CHICAGO — Smoking before menopause, especially prior to giving birth, may be associated with a modest increase in the risk of developing breast cancer, according to a report in the Jan. 24 issue of Archives of Internal Medicine.

May 19, 2010

Danish drug maker Novo Nordisk will remove 25 microgram doses of a treatment for atrophic...

May 17, 2010

A branded drug made by Teva Pharmaceutical Industries reduced the frequency of nighttime awakenings due...